Filing Details
- Accession Number:
- 0001628280-22-027122
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-10-26 20:00:34
- Reporting Period:
- 2022-10-24
- Accepted Time:
- 2022-10-26 20:00:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1894562 | Prime Medicine Inc. | PRME | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1922939 | Thomas Cahill | C/O Prime Medicine, Inc. 21 Erie Street Cambridge MA 02139 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-10-24 | 4,905,679 | $0.00 | 4,905,679 | No | 4 | C | Indirect | By Newpath Partners, L.P. |
| Common Stock | Acquisiton | 2022-10-24 | 400,000 | $17.00 | 5,305,679 | No | 4 | P | Indirect | By Newpath Partners, L.P. |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By Newpath Partners, L.P. |
| No | 4 | P | Indirect | By Newpath Partners, L.P. |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2022-10-24 | 9,999,999 | $0.00 | 3,216,674 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2022-10-24 | 5,250,781 | $0.00 | 1,689,005 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (together, the "Preferred Stock") were convertible into Common Stock on a one-for-3.10880 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on October 24, 2022. The Preferred Stock had no expiration date.
- Represents shares held directly by Newpath Partners, L.P. ("Newpath LP"). Newpath Partners GP, L.P. ("Newpath GP LP") is the general partner of Newpath LP. Newpath Partners GP, LLC ("Newpath GP LLC") is the general partner of Newpath GP LP. The Reporting Person is a managing member of Newpath GP LLC, and disclaims beneficial ownership of the shares held directly by Newpath LP except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
- Reflects shares purchased by Newpath LP in the Issuer's initial public offering.
Billionaire Hedge Funds
